Vimarsana
Biggest News Aggregation in the World

Page 24 - Jeff Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Mclaughlin Today - Breaking & Trending Today

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 ... - Vimarsana News

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 ... Vir Biotechnology, Inc.May 7, 2021 GMT – Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 – – Review will support a formal Marketing Authorization Application – – GSK and Vir continue discussions with global regulators to make sotrovimab available to patients with COVID-19 – ...

Source: apnews.com
Pools remain in high demand; chlorine could run low - Vimarsana News

Pools remain in high demand; chlorine could run low

5/5/2021 Above Ground Back Yard Pool By LAUREN CLEM and, JACQUELYN MOOREHEAD Demand for pools remains very high as Rhode Island moves toward its 2021 swimming season, but local pool store owners say they currently have enough chlorine on the shelves for now. National news outlets are warning that a chlorine shortage could throw a wrench in the summer season, and Jeff McLaughlin, of Branch Village Pool & Spa Needs in North Smithfield, said that while he’s heard of other areas dealing with a shortage in chlorine tablets, he hasn’t had a problem yet this year. The North Smithfield store, he ...

FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer - Vimarsana News

FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

Share this article Share this article LONDON, April 22, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company's Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This ...

Wrather reopens with traveling Smithsonian exhibit - Vimarsana News

Wrather reopens with traveling Smithsonian exhibit

Wrather reopens with traveling Smithsonian exhibit Posted By: Features Editor March 31, 2021 Dionte Berry @murraystate.edu The Wrather Museum is opening back up after its COVID-19 closure with the traveling Smithsonian exhibit: “Voices and Votes: Democracy in America.” Along with the Smithsonian exhibit, Wrather Museum also hosts a WKMS exhibit, which shares the history of the radio station, and the Murray Room, which displays pieces of Murray’s past and details Murray State’s history.  With the rest of the University, Wrather closed down in March 2020 because of COVID-19 and re...

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate - Vimarsana News

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate Fast Track designation granted by US FDA Feasibility study initiated of a vaccine candidate to address emerging variants Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of hea...